GSK struck a deal to buy the rights to CureVac’s Covid-19 and flu vaccines for up to $1.56 billion, in a bid to regain ground lost to newcomers to the vaccine market during the pandemic.
Trending
- Race to contain ebola outbreak in war-torn DRC where weak infrastructure hampers response
- Russian Andreeva beats Poland's Chwalinska to win French Open title
- Germany beat USA before World Cup but injuries cast shadow
- Leila Farzad on not being able to return to Iran: ‘Going back got more complicated and dangerous’
- How the Job Market Is Leaving New Graduates Behind
- South Korean labour minister to mediate talks as Samsung faces strike threat
- ‘Don’t regulate flexible work out of existence’, retail industry warns
- Brad Bird’s Passion-Project Ray Gunn Will Be ‘A Really Good Time’
